WOODBRIDGE, ON, Oct. 9, 2012 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CNSX: PVO), a specialty pharmaceutical company with a focus on cardiovascular
disease and overall health, is pleased to announce that the company
will be exhibiting at the 2012 Cardiometabolic Health Congress (CMHC)
in Boston, MAOctober 10-13, 2012 Booth #513. The CMHC attracts over
1000 U.S. based practicing clinicians and provides a forum for the most
current information on preventing, diagnosing and managing
cardiovascular and metabolic disorders.
"This is the perfect venue to showcase VASCAZENTM and educate prescribing physicians on the benefits of our superior and
unique prescription only Omega-3," said Dr. George Jackowski, Chief
Scientific Officer. "Our studies indicate that the majority of
cardiovascular patients are deficient in Omega-3 and by correcting this
deficiency with VASCAZENTM it allows physicians to prescribe an Omega-3 therapy to a broader
cardiovascular patient population than what is currently on the
market."
About Pivotal Therapeutics Inc.
With offices in Toronto, Canada and Boca Raton, Florida, Pivotal
Therapeutics is a publicly traded (OTCQX: PVTTF); (CNSX: PVO) specialty
pharmaceutical company with a focus on cardiovascular disease and
overall health. Pivotal Therapeutics' lead product VASCAZENTM is a prescription only Medical Food formulated to meet the dietary
Omega-3 deficient needs of patients with cardiovascular disease through
elevating Eicosapentaenoic acid (EPA) and Docosahexaenoic acid (DHA) to
levels associated with reduced risk of cardiovascular complications.
VASCAZENTM is a >90% pure, proprietary EPA:DHA fatty acid formulation, protected
by a series of both issued and pending U.S. and foreign patents and
commercialized as a prescription only Medical Food in the U.S. This
unique formulation will provide the cornerstone upon which a family of
cutting edge combination products, with efficacy across a broad
spectrum of cardiac care, will be commercialized.
OMAZENTM is a >90% pure, proprietary EPA:DHA fatty acid formulation
commercialized for sale and distribution in Canada for the maintenance
of good health through elevating Omega-3 fatty acid levels. The unique
formulation and dosage will be available to patients and consumers who
realize the health benefits of Omega-3 supplementation with a quality
product.
Disclosure Notice
The information contained in this document is as of October 9, 2012.
This press release contains forward-looking statements. Such
forward-looking statements are subject to a number of risks,
assumptions and uncertainties that could cause Pivotal's actual results
to differ materially from those projected in such forward-looking
statements. These statements can be identified by the use of words such
as "will", "anticipate", "estimate", "expect", "project", "forecast",
"intend", "plan", "believe", "project", "potential", and similar
expressions with any discussion of future operating or financial
performance or events. In particular, factors that could cause actual
results to differ materially from those in forward looking statements
include the following: Pivotal's inability to obtain additional
financing on acceptable terms; growth in costs and expenses; inability
to compete with others who provide comparable products; risk that the
Company's products will not gain widespread market acceptance; risks
relating to the Company's ability to maintain its CSNX listing.
Forward-looking statements speak only as of the date made and are not
guarantees of future performance. The Company undertakes no obligation
to publicly update or revise any forward-looking statements contained
in this document as a result of new information or future events or
developments. CNSX has not reviewed and does not accept responsibility
for the adequacy or accuracy of this information.
SOURCE Pivotal Therapeutics Inc.